Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J S Rustin

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
British Journal of Cancer|March 18, 2004
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumoursI A McNeish, E J Kanfer, R Haynes, et al.
British Journal of Cancer|January 13, 2006
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancerP A Vasey, R Atkinson, R Osborne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2005
Clinical trials in ovarian carcinoma: study methodologyJ B Vermorken, M K B Parmar, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancerM Zweifel, G C Jayson, N S Reed, et al.
British Journal of Cancer|August 28, 2003
A phase 1 study of tazarotene in adults with advanced cancerP H Jones, R D Burnett, I Fainaru, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
British Journal of Cancer|March 18, 2004
Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumoursI A McNeish, E J Kanfer, R Haynes, et al.
British Journal of Cancer|January 13, 2006
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancerP A Vasey, R Atkinson, R Osborne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2005
Clinical trials in ovarian carcinoma: study methodologyJ B Vermorken, M K B Parmar, M F Brady, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancerM Zweifel, G C Jayson, N S Reed, et al.
British Journal of Cancer|August 28, 2003
A phase 1 study of tazarotene in adults with advanced cancerP H Jones, R D Burnett, I Fainaru, et al.
Lancet (London, England)|July 26, 2005
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trialR T D Oliver, M D Mason, G M Mead, et al.
British Journal of Cancer|March 20, 2014
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancerR M Glasspool, R Brown, M E Gore, et al.
ESMO Open|February 20, 2021
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trialJ A Ledermann, A C Embleton-Thirsk, T J Perren, et al.
Pageof 3